Pathology characteristics of ocular von Hippel-Lindau disease with neovascularization of the iris and cornea: A case report

被引：10
作者：
Chen S. [1 ,2 ]
Chew E.Y. [3 ]
Chan C.-C. [1 ]
机构：
[1] Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD
[2] Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou
[3] Division of Epidemiology and Clinical Research, National Eye Institute, National Institutes of Health, Bethesda, MD
来源：
Journal of Medical Case Reports | / 9卷 / 1期
关键词：
Cornea; Iris; Neovascularization; Retinal hemangioblastoma; von Hippel-Lindau disease;
D O I：
10.1186/s13256-015-0539-2
中图分类号：
学科分类号：
摘要：
Introduction: Retinal hemangioblastoma is one of the most common tumors in von Hippel-Lindau disease. In addition to the classical pathological characteristics of von Hippel-Lindau disease, we report, for what we believe to be the first time, a severe and rare ocular complication characterized by neovascularization in the cornea and iris. Case presentation: A 41-year-old white man with a long history of retinal hemangioblastoma presented with neovascularization of his iris and cornea as well as corneal perforation. His right eye was blind and painful, leading to a decision of enucleation. On microscopy, the enucleated eye showed neovascularization of the cornea and iris. The cornea was perforated with an expulsive hemorrhage and extruding intraocular contents, including the retina. A large retinal hemangioblastoma was located at the posterior pole adjacent to the optic nerve head. The tumor was mainly composed of large cells with foamy cytoplasm. Bone formation was also present. Conclusion: Our pathology findings were consistent with previously described features of retinal hemangioblastoma. The present case is unusual because of the co-existing neovascularization in the iris and cornea, which may have led to corneal perforation and vision loss. © 2015 Chen et al.; licensee BioMed Central.
引用
收藏
相关论文
共 15 条
  • [1] Kaelin Jr.W.G., Molecular basis of the VHL hereditary cancer syndrome, Nat Rev Cancer., 2, pp. 673-682, (2002)
  • [2] Lonser R.R., Glenn G.M., Walther M., Chew E.Y., Libutti S.K., Linehan W.M., Et al., Von Hippel-Lindau disease, Lancet., 361, pp. 2059-2067, (2003)
  • [3] Wong W.T., Agron E., Coleman H.R., Tran T., Reed G.F., Csaky K., Et al., Clinical characterization of retinal capillary hemangioblastomas in a large population of patients with von Hippel-Lindau disease, Ophthalmology., 115, pp. 181-188, (2008)
  • [4] Webster A.R., Maher E.R., Moore A.T., Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation, Arch Ophthalmol., 117, pp. 371-378, (1999)
  • [5] Mottow-Lippa L., Tso M.O., Peyman G.A., Chejfec G., Von Hippel angiomatosis. A light, electron microscopic, and immunoperoxidase characterization, Ophthalmology., 90, pp. 848-855, (1983)
  • [6] Chan C.C., Vortmeyer A.O., Chew E.Y., Green W.R., Matteson D.M., Shen D.F., Et al., VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma, Arch Ophthalmol., 117, pp. 625-630, (1999)
  • [7] Singh A.D., Shields C.L., Shields J.A., Von Hippel-Lindau disease, Surv Ophthalmol., 46, pp. 117-142, (2001)
  • [8] Wong W.T., Yeh S., Chan C.C., Kalina R.E., Kinyoun J.L., Folk J.C., Et al., Retinal vascular proliferation as an ocular manifestation of von Hippel-Lindau disease, Arch Ophthalmol., 126, pp. 637-643, (2008)
  • [9] Chan C.C., Collins A.B., Chew E.Y., Molecular pathology of eyes with von Hippel-Lindau (VHL) Disease: A review, Retina., 27, pp. 1-7, (2007)
  • [10] Grossniklaus H.E., Thomas J.W., Vigneswaran N., Jarrett W.H., Retinal hemangioblastoma. A histologic, immunohistochemical, and ultrastructural evaluation, Ophthalmology., 99, pp. 140-145, (1992)
12